extract: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025
Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>
This commit is contained in:
Teleo Agents
parent
e64c062373
commit
7bc2c82d7c
2 changed files with 27 additions and 1 deletions
|
|
@ -45,6 +45,18 @@ ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker)
|
|||
|
||||
ESC 2024 mediation analysis quantifies specific mediator contributions: hsCRP (inflammation) accounts for 42.1% of CV benefit, body weight only 19.5%, waist circumference 64.0%. Joint mediation of ALL measured factors (weight, inflammation, HbA1c, waist) explains only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% unexplained. This confirms the weight-independence finding from the Lancet 2025 prespecified analysis and adds the specific breakdown showing inflammation mediates MORE than weight loss.
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
|
||||
|
||||
SELECT trial prespecified analysis (N=17,604, published Lancet Nov 2025) confirms ~67% of MACE reduction is independent of weight/adiposity changes. Treatment effect was consistent across ALL baseline BMI and waist circumference categories with no evidence of heterogeneity. Time-varying weight loss analysis showed 'no evidence that the treatment effect of semaglutide was mediated by time-varying weight loss.' Only ~33% of benefit explained by early waist circumference reductions. This is stronger evidence than the ESC 2024 abstract because it's a prespecified (not exploratory) analysis from the definitive SELECT publication.
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30*
|
||||
|
||||
ESC 2024 mediation analysis (Colhoun/Lincoff) converges on same conclusion via different methodology: body weight mediates only 19.5% of CV benefit, while hsCRP (inflammation marker) mediates 42.1% - the largest single measured factor. Joint mediation of all measured metabolic/adiposity parameters: 31.4%, leaving ~68.6% pleiotropic/unexplained. The two independent analyses (prespecified SELECT and ESC mediation) both arrive at 67-69% weight-independence through different statistical approaches.
|
||||
|
||||
|
||||
|
||||
|
||||
Relevant Notes:
|
||||
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
|
|
|
|||
|
|
@ -7,9 +7,13 @@ date: 2025-11-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: journal-article
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mechanism, adiposity, MACE]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-30
|
||||
enrichments_applied: ["semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md", "semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -56,3 +60,13 @@ tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mec
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: Closes active thread on GLP-1 CV mechanism; establishes weight-independence as the primary clinical finding; connects GLP-1 benefit to SDOH-generated inflammatory pathways
|
||||
EXTRACTION HINT: Focus on the 67-69% weight-independence figure and the hsCRP mediation (42.1%) — together these establish the anti-inflammatory mechanism. Extract as mechanism claim, not just efficacy claim. Consider whether this should be a divergence with the existing GLP-1 claim that frames the drug primarily through metabolic/weight-loss lens.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- SELECT trial enrolled 17,604 adults ≥45 with BMI ≥27, pre-existing CVD, no diabetes at baseline
|
||||
- Semaglutide 2.4mg weekly vs placebo
|
||||
- Primary outcome: MACE (cardiovascular death, non-fatal MI, non-fatal stroke)
|
||||
- Published in The Lancet, November 2025
|
||||
- Led by John Deanfield (UCL) and colleagues
|
||||
- Approximately 33% of MACE reduction explained by early reductions in waist circumference
|
||||
- ESC 2024 mediation analysis showed hsCRP mediated 42.1% of benefit, body weight 19.5%
|
||||
|
|
|
|||
Loading…
Reference in a new issue